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determination. 22 drugs met NICE’s EOL-SPP for the indication for which they were
being appraised. Twelve of these drugs had the EOL-SPP criterion applied to the
only indication for which they were licensed. The EOL-SPP criterion was applied to
the cumulative populations of ten drugs which had marketing authorization for
more than one indication. The seven drugs that did not meet the EOL-SPP criterion
all had individual indications which were within the number of what is considered
acceptable (7,000), but had total cumulative populations that were greater. Two
STAs in particular stand out. The appraisal committee accepted that panitumumab
met the EOL-SPP criterion for its current indication but noted that the EMA recom-
mended a marketing extension which would raise the expected patient population
to 10,000. In its final appraisal determination for abiraterone NICE overturned its
original decision that the drug did not meet the EOL-SPP criterion, even though it
noted that abiraterone may be recommended for a marketing extension for a
greater patient population. CONCLUSIONS: There is no evidence to suggest NICE
applies the EOL-SPP to the cumulative populations of currently licensed indications
plus potential future indications.
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OBJECTIVES: To compare the contrasting approaches in France and the UK for
assessing the value added by new drugs METHODS: We reviewed the technology
appraisals performed by the National Institute for Health and Clinical Excellence
(NICE) on 38 anticancer drugs in the UK from September 2003 to January 2012.
Estimates of the quality-adjusted life-years (QALYs) gained and incremental cost
per QALY gained were then compared the assessments of the Amélioration du
Service Médical Rendu (ASMR) made by the Haute Autorité de Santé (HAS) in France
for the same drugs in the same clinical indications. RESULTS: In the UK, the esti-
mates of QALYs gained ranged from 0.018 to 1.85 and estimates of incremental
cost-per QALY from £1800 to £458,000. The estimate of incremental cost per QALY
was a good predictor of the level of restriction imposed on the use of the drug
concerned. Patient access schemes, which normally imply price reductions, were
proposed in 45% of cases. In France, the distribution of ASMRs was 1, 16%; 2, 8%; 3,
21%; 4, 24%; 5, 24%; and uncategorized/ non-reimbursed, 8%. Since ASMRs of 4 and
above signify minor or no improvement over existing therapy, these ratings imply
that, in around half the cases, the drugs concerned would face price controls.
Overall, the assessments of value added in the two jurisdictions produced very
similar results. A superior ASMR rating was a good predictor of both higher QALYs
gained and a lower incremental cost per QALY. CONCLUSIONS: We conclude that,
despite the contrasting approaches employed in France and the UK for assessing
the value added by new drugs, the overall assessments of value added produced
very similar results. However, the implications of these assessments for patient
access to, and prices of, anticancer drugs in the two jurisdictions require further
investigation.
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OBJECTIVES: To examine the similarities and differences in the HTAs conducted in
6 countries in the last 5.5 years in the areas of cardiology and oncology, the thera-
peutic areas of greatest mortality. METHODS: We reviewed and abstracted infor-
mation from 768 cardiology and 960 oncology HTAs conducted from January 1, 2007
to June 23, 2012. Our primary focus was those made by the following public orga-
nizations: Canadian Agency for Drugs and Technology in Health, Haute Autorite de
Sante, Institute for Quality and Efficiency in Health Care, National Institute for
Clinical Excellence, Pharmaceutical Benefits Advisory Committee, Medical Services
Advisory Committee, and the Agency for Healthcare Research and Quality. For
comparative purposes and overall interest, we also studied the HTAs of the follow-
ing private American organizations: BlueCross BlueShield Technology Evaluation
Center, California Technology Assessment Forum, Drug Effectiveness Review Pro-
gram, Healthcore/Wellpoint, Institute for Clinical and Economic Review, and the
MedCo Research Institute, and the multinational Cochrane Collaboration. Finally,
we looked at the American Recovery and Reinvestment Act generated CER grants
recently made by the federal government to the National Institutes of Health and
the Department of Health and Human Services to determine any new directions in
the US. Cardiology HTAs were divided into 12 sub-therapeutic categories; oncology
18 for ease of analysis. Variables analyzed included specific subject of HTA and
analytic methods, date of release, and results. RESULTS:Market entry of drugs and
selected devices tended to affect HTA content and timing; country processes for
review also affect these variables and results. HTAs of other single interventions
and multiple modality comparisons were more variable as to timing, content, and
results.CONCLUSIONS: Both the commonalities and differences found in the HTAs
lend themselves to the examination of potential economies of evidence assess-
ment and bases for optimal patient care. The authors provide suggestions for policy
makers.
PCN152
PATIENT-RELEVANT ENDPOINTS (PRE) IN ONCOLOGY - CURRENT ISSUES IN
THE CONTEXT OF EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY: AN
INDUSTRY PERSPECTIVE
Dabisch I1, Dethling J2, Dintsios CM1, Drechsler M3, Kalanovic D4, Kaskel P5, Langer F6,
Ruof J7, Ruppert T1, Wirth D8
1German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany,
2GlaxoSmithKline GmbH & Co. KG, Munich, Germany, 3Boehringer Ingelheim Pharma GmbH &
Co. KG, Ingelheim, Germany, 4Pfizer Deutschland GmbH, Berlin, Germany, 5MSD Sharp Dohme
GmbH, Haar (Munich), Germany, 6Lilly Deutschland GmbH, Bad Homburg, Germany,
7Medizinische Hochschule Hannover, Hannover, Germany, 8Janssen-Cilag GmbH, Neuss,
Germany
OBJECTIVES: The German AMNOG health care reform includes a mandatory EBA of
innovative medicines at launch. As per German social code, EBA is based on regis-
tration trials and must include evaluation of the patient-relevant, therapeutic ef-
fect of the new medicines compared to an appropriate comparator as defined by
the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled
issues regarding the acceptance of some PRE as G-BA and IQWiG are grading the
endpoints, focusing on overall survival (OS) as the preferred endpoint in oncology.
METHODS:A task force under the auspices of the German Association of Research-
based Pharmaceutical Companies (vfa) was appointed. Members were experienced
German outcomes research, medical, HTA and biostatistics researchers in indus-
try. After agreement on core assumptions developed and outlined by the Task
Force, a draft position was prepared. Input on iterative versions was solicited from
a panel of reviewers from industry and external stakeholders. RESULTS: Distinc-
tive features of registration trials in oncology need to be considered when these
studies form basis for EBA, especially in cancer indications with long post-progres-
sion survival time; and with several consecutive therapeutic options available fol-
lowing progression. Besides, ethical committees, caregivers and patients often de-
mand cross-over-designs diluting over the treatment effect on OS. Also, regulatory
authorities require evaluation of morbidity-related study endpoints including sur-
vival of patients without their disease getting worse (i.e., progression-free survival).
Fear of progression is a key feature in oncological conditions. Furthermore progres-
sion usually requires treatment changes, another strong indicator for its relevance
to patients. CONCLUSIONS: PRE in oncology depend on tumor- and tumor-stage-
specific factors. For decades, endpoints have been thoroughly evaluated, resulting
in specific guidelines and clinical trial programs that were developed in-line with
regulatory guidance. This extensive knowledge and experience should be fully
acknowledged during EBA when assessing the patient-relevant benefit of innova-
tive medicines in oncology.
PCN153
APPLICATION OF REAL WORLD DATA TO INFORM A BREAST CANCER DECISION
- ANALYTIC MODEL IN AUSTRIA AND THE U.S - PRELIMINARY OUTCOMES OF
DATA COLLECTION
Jahn B1, Stenehjem D2, Saverno KR3, Rochau U4, Cai B2, Siebert U5, Brixner D6
1UMIT - University for Health Sciences, Medical Informatics and Technology; Oncotyrol - Center
for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 2University of Utah, Salt
Lake City, UT, USA, 3UMIT- Univ. for Health Sciences, Medical Informatics and Technology, Hall
i.T., Austria; Univ. of Utah, Salt Lake City, USA, Hall i.T.;Innsbruck, Tyrol, Austria, 4UMIT;
Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 5UMIT/
Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 6University of Utah, College of
Pharmacy, Salt Lake City, UT, USA
OBJECTIVES: A Breast Cancer Outcomes & Policy (BCOP) microsimulation model is
being developed to evaluate the 21-gene recurrence score assay that guides adju-
vant chemotherapy in Austria. The goal is to adapt the model to a United States
(US) context using real-world data from the Huntsman-Cancer-Institute (HCI) in
Utah. We aim to study the impact of real-world data and country-specific settings
on cost-effectiveness results. METHODS: The BCOP-model simulates a hypotheti-
cal cohort of 50year old women over a lifetime time horizon using a discrete-event-
simulation. To inform this model, a cohort of early breast cancer patients was
identified at the HCI based on ICD-9 codes(174.0-174.9) and inclusion in the HCI
registry for invasive breast cancer from 2005-2010. Patients were included with
stage I to IIIa disease at diagnosis, documented curative intent surgery, use of
endocrine therapy, and lack of HER2 directed therapies. Patients receiving adjuvant
chemotherapy were identified. Price for chemotherapy was based on average
wholesale price (AWP). RESULTS: A total of 367 patients with early stage breast
cancer were identified with a mean age of 58.2 years. There were 123 patients
(33.5%) treated with adjuvant chemotherapy. Among the 123 patients treated with
chemotherapy, 21%, 64.2% and 14.6% were stage I, II and IIIa respectively; which
comprised 12.3%, 57.7%, and 64.3% of all stage I, II, and IIIa patients, respectively.
The predominate chemotherapy regimen was doxorubicin and cyclophosphamide
with or without paclitaxel for 72% of patients. The AWP for this regimen is $4476
with and $1507 without paclitaxel, respectively; the AWP of Oncotype Dx is $4175.
One of the challenges faced during model development was that many of the
variables needed require chart reviews. CONCLUSIONS: Extraction of data from a
real-world breast cancer cohort provided reference data on treatments and costs to
inform the BCOP- model.
PCN154
ARE POPULATION-BASED REGISTRIES A SUITABLE TOOL FOR OUTCOMES
RESEARCH IN CANCER? EXPERIENCES FROM FOUR REGISTRIES
de Groot S, Blommestein H, Franken M, Uyl-de Groot C
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: Population-based registries provide insights into quality of care and
inform reimbursement decisions. This study aims to investigate whether registries
are a suitable tool for outcomes research in assessing drug use and real-world
cost-effectiveness in cancer. METHODS: We used four Dutch population-based
registries to conduct outcomes research. Patients for the registries were included
regardless of prognosis or treatment: 55% and 40% of all Dutch patients in meta-
static renal cell cancer (mRCC) and three haematological cancers, respectively.
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